PeptideStack
5.2kquestions
20kanswers
220users

How do I model twelve months of semaglutide across supply routes?

Asked 19 Dec 2024Modified 16 months agoViewed 17k times
33

I would rather spend on verification than on volume.

Please show the division. I want to check my own against yours.

I would like the general form as well as the specific number, so I can apply it again.

How many significant figures are actually justified here?

cost-analysis
cost-analysis

Cost arithmetic done honestly: cost per milligram after dead-space loss, list versus net price, comparing a multi-dose vial to a fixed-dose pen,…

260 questions
insurance
insurance

Coverage: formulary tiers, exclusion versus non-coverage, the difference a diabetes indication makes, employer carve-outs, and what an appeal…

35 questions
compounding
compounding

Compounded preparations: what a 503A and a 503B facility may legally prepare and when, base versus salt forms, beyond-use dating under USP…

61 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
shareeditfollowflag
LQ
askedlipid_panel_q36k12719 Dec 2024
4Same question before my first order, and the small-order-then-test route worked. – tobias_maartens 6 months ago
3Do you have a certificate in front of you, or are you asking before requesting one? – Dr_Fatima_Belkacem 4 months ago
add a comment

5 Answers

Accepted answer first, then by votes
8

Accepted answer

Twelve months is 52 weekly administrations across 365 days, and on a four-week ladder from the bottom of the range about 5 steps — so roughly 20 of the 52 doses are escalation doses and 32 are at maintenance. Model it in that order and the routes become comparable: doses per year first, milligrams per dose second, cost per milligram third. Anything quoted per vial hides the second of those, which is the one that changes most between the first 20 doses and the last 32. Then add what each route charges that the other does not. A prescription route carries consultation and dispensing fees, spread across the 52 doses rather than paid once. A research route carries testing, shipping, and the material lost between them. Testing is the line most sheets omit. At one lot a quarter, a test-every-lot policy is 4 assays a year; at one lot a month it is 12. That difference is usually larger than any difference in price per milligram, and it is a policy you choose rather than a cost you are quoted. Put doses per year in the top row and derive everything under it, and the twelve-month totals compare on arithmetic instead of on presentation.

The relevant arithmetic is that a fifteen per cent price advantage disappears against a ten per cent content shortfall plus a testing cost.

Worked example. Supplier A: £60 for a 10 mg vial, content 96 per cent, so 9.6 mg for £60, or £6.25/mg before carriage. Supplier B: £52 for the same nominal vial, content 88 per cent, so 8.8 mg for £52, or £5.91/mg. B still wins here, but the gap has narrowed from thirteen per cent on the label to five per cent in reality.

Carriage amortises across the order. Twenty-five pounds of carriage on one vial is £2.50/mg on a 10 mg vial; on ten vials it is £0.25/mg. That single term explains most of the case for larger, less frequent orders.

Independent testing prices at the services this community uses are published and are stable enough to model.

A spreadsheet built on label claim rather than measured content is precise about the wrong number.

Larger orders are cheaper per milligram and concentrate lot risk. Price both.

shareimprove this answerflag
GA
answered · acceptedgrainne_ahearn50k3822 Mar 2025
7Does the same reasoning hold for a group order, where one lot covers everybody? – s_bhattacharya 8 days ago
6Thank you — the checklist format makes this actionable rather than merely correct. – aine_mulcahy 9 months ago
add a comment
Sponsored

PeptideMeter - Independent Peptide Analytics

Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.

Browse results
10

Specifically, this is a spreadsheet question and doing it properly changes conclusions more often than people expect.

Change one number and it reverses: if B assays at 82 per cent, that is 8.2 mg for £52, or £6.34/mg, and the cheaper vial is now the more expensive peptide.

The part that matters: cost per milligram is the wrong metric entirely if you are optimising for confidence rather than price, and it is worth saying which one you are doing before you build the spreadsheet.

Published content assay results across the independent services show nominal and measured content differing by one to ten per cent, which is the term that makes label-price comparisons unreliable.

Divide by measured content, not by label claim. That is the whole correction.

shareimprove this answerflag
C3
answeredcharge_state_316k3813 Apr 2025
5

Answering this needs the order size, because carriage and testing amortise very differently across one vial and across ten.

Dead-space loss is small with fixed-needle insulin syringes — a few microlitres per draw — and substantial with detachable-needle luer syringes at 35 to 100 microlitres. Across twenty draws that is up to two millilitres of solution.

The full calculation: (unit price + carriage share + testing share) ÷ (nominal mg × measured content fraction × (1 − dead-space and wastage fraction)). Every term after the first is routinely omitted.

Include carriage and testing as per-milligram terms. They dominate small orders.

shareimprove this answerflag
IB
answeredilaria_bertone33k3825 Dec 2024
6I have kept every invoice and declaration, which I gather is the useful habit. – Dr_Tomas_Kral 6 months ago
add a comment
2

The short version: unit price, carriage, testing, dead-space loss and wastage. The first is the one everybody compares and rarely the one that decides it.

Wastage from a reconstituted vial discarded at the end of its in-use period is a genuine cost, and it is a function of the diluent volume chosen at reconstitution rather than of anything the supplier did.

Larger orders reduce cost per milligram and increase exposure to a single lot, which is a real trade rather than a free win.

Decide whether you are optimising cost or confidence before you build the model.

shareimprove this answerflag
DL
answeredDr_Otto_Lindqvist72k582 Apr 2025
1

Start by listing every cost in the chain, since carriage, testing and wastage frequently exceed the difference in headline price.

Independent testing costs roughly the price of one to two vials at the services this community uses. On a two-vial order that is a fifty to a hundred per cent surcharge; on a twenty-vial order it is five per cent.

Syringe dead-space volumes are published per design, with fixed-needle insulin syringes under 5 microlitres and conventional luer designs at 35 microlitres or more.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Fixed-needle syringes save more peptide than most price differences do.

shareimprove this answerflag
DO
answeredDr_Malik_Osei19k2728 Jan 2025

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.